Blueprint Medicines Corporation (BPMC)
NASDAQ: BPMC · Real-Time Price · USD
90.14
+1.21 (1.36%)
At close: Dec 20, 2024, 4:00 PM
90.00
-0.14 (-0.16%)
After-hours: Dec 20, 2024, 4:55 PM EST
Blueprint Medicines Employees
Blueprint Medicines had 655 employees as of December 31, 2023. The number of employees increased by 14 or 2.18% compared to the previous year.
Employees
655
Change (1Y)
14
Growth (1Y)
2.18%
Revenue / Employee
$663,229
Profits / Employee
-$195,495
Market Cap
5.73B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 655 | 14 | 2.18% |
Dec 31, 2022 | 641 | 146 | 29.49% |
Dec 31, 2021 | 495 | 66 | 15.38% |
Dec 31, 2020 | 429 | 46 | 12.01% |
Dec 31, 2019 | 383 | 166 | 76.50% |
Dec 31, 2018 | 217 | 68 | 45.64% |
Dec 31, 2017 | 149 | 43 | 40.57% |
Dec 31, 2016 | 106 | 25 | 30.86% |
Dec 31, 2015 | 81 | 20 | 32.79% |
Dec 31, 2014 | 61 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Elanco Animal Health | 9,800 |
Merit Medical Systems | 6,950 |
Stevanato Group | 5,634 |
Tempus AI | 1,952 |
Inspire Medical Systems | 1,011 |
Ionis Pharmaceuticals | 927 |
Cytokinetics | 423 |
Halozyme Therapeutics | 373 |
BPMC News
- 3 days ago - Blueprint Medicines to Present at the 43rd Annual J.P. Morgan Healthcare Conference - PRNewsWire
- 14 days ago - Blueprint Medicines' Continued Leadership in Redefining the Standard of Care in Systemic Mastocytosis Highlighted at 2024 ASH Annual Meeting - PRNewsWire
- 5 weeks ago - Blueprint Medicines' Growth With AYVAKIT And Next-Gen Oncology Drugs - Seeking Alpha
- 5 weeks ago - Blood Cancer-Focused Blueprint Medicines Could Be 'Attractive Target For Partnerships': Analyst - Benzinga
- 7 weeks ago - Blueprint Medicines Corporation (BPMC) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - Blueprint Medicines Reports Third Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance - PRNewsWire
- 2 months ago - Blueprint Medicines to Report Third Quarter 2024 Financial Results on Wednesday, October 30, 2024 - PRNewsWire
- 3 months ago - The Schall Law Firm Has Launched An Inquiry Into Whether Blueprint Medicines Corporation Violated Securities Laws And Impacted Investors Are Invited To Join - Accesswire